Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: oral Placebo Clear all
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine

NCT00775463
View directory record Official record
Conditions
Systemic Sclerosis, Scleroderma
Interventions
treprostinil diethanolamine, placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
24
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Sep 25, 2026, 1:36 PM EDT
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Recruiting Phase 2 Interventional

Tenapanor in Synucleinopathy-Related Constipation

NCT06460038
View directory record Official record
Conditions
Synucleinopathy, Parkinson's Disease
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Cedar Valley Digestive Health Center
Other
Eligibility
50 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Waterloo, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Recruiting Phase 3 Interventional

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

NCT07196748
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Icotrokinra, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
56
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional

Celecoxib in Preventing Lung Cancer in Former Heavy Smokers

NCT00055978
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib, placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 19, 2011 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Effects of DHEA in Pulmonary Hypertension

NCT03648385
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
DHEA tablet, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

NCT00890825
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
AZD6244, docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients

NCT02272634
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
YPL-001 80 mg, YPL-001 160 mg, Placebo
Drug
Lead sponsor
Yungjin Pharm. Co., Ltd.
Industry
Eligibility
30 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • Winter Park, Florida • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome

NCT03355209
View directory record Official record
Conditions
Lennox Gastaut Syndrome
Interventions
ZX008 0.2 or 0.8 mg/kg/day, Matching Placebo
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

NCT00105521
View directory record Official record
Conditions
Parkinson's Disease, Dyskinesia
Interventions
Sarizotan, Placebo
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
30 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)

NCT01027884
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Ambulatory Care
Interventions
Placebo, Idebenone
Drug
Lead sponsor
Santhera Pharmaceuticals
Industry
Eligibility
10 Years to 18 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
9
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

NCT01120249
View directory record Official record
Conditions
Kidney Cancer
Interventions
everolimus, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
1,545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1002
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria

NCT00283387
View directory record Official record
Conditions
Hyperoxaluria
Interventions
Betaine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
6 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Sep 25, 2026, 1:36 PM EDT
Active, not recruiting Phase 4 Interventional

Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing

NCT07281014
View directory record Official record
Conditions
Heart Failure
Interventions
Placebo, Spironolactone 25mg, Aldosterone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ozanimod, Interferon beta-1a, Placebo to ozanimod, Placebo to interferon beta-1a
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT00516321
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
47
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Results available

Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women

NCT01965704
View directory record Official record
Conditions
Narcotic Addiction, Neonatal Abstinence Syndrome
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 45 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
8
States / cities
San Francisco, California • San Jose, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 25, 2026, 1:36 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

MLN3126 Single Rising Dose Study

NCT02447458
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MLN3126, MLN3126 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Sep 25, 2026, 1:36 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

NCT04208178
View directory record Official record
Conditions
Advanced HER2+Breast Cancer
Interventions
Alpelisib, Alpelisib matching Placebo, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Fayetteville, Arkansas • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions
AZD4901 (oral), Placebo to match AZD4901
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

NCT01525615
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol
Device · Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2016 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Determine the Bioavailability of Oral Beta-Aminoisobutyric Acid (BAIBA) Ingestion

NCT05328271
View directory record Official record
Conditions
Absorption; Chemicals
Interventions
Beta-Aminoisobutyric Acid
Dietary Supplement
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 25, 2026, 1:36 PM EDT
Completed Phase 3 Interventional Results available

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 25, 2026, 1:36 PM EDT